For research use only. Not for therapeutic Use.
Blarcamesine (Cat No.:I003303) is an investigational small-molecule drug that acts as a selective sigma-1 receptor agonist with additional muscarinic receptor activity. It is being developed for neurodegenerative and neurodevelopmental disorders, including Alzheimer’s disease, Parkinson’s disease, and Rett syndrome. By modulating cellular stress responses, calcium homeostasis, and mitochondrial function, Blarcamesine is thought to protect neurons and enhance synaptic plasticity. Clinical studies suggest potential benefits in cognition, memory, and daily functioning, making it a promising candidate for novel therapies targeting central nervous system disorders.
| CAS Number | 195615-83-9 |
| Synonyms | 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine |
| Molecular Formula | C19H23NO |
| Purity | ≥95% |
| IUPAC Name | 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine |
| InChI | InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3 |
| InChIKey | BOTHKNZTGGXFEQ-UHFFFAOYSA-N |
| SMILES | CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3 |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
